AGP Picks
View all

Cloud-based rare disease family registry market seen reaching $3.15 billion by 2030

9 hours ago
Cloud-based rare disease family registry market seen reaching $3.15 billion by 2030
By AI, Created 17:30 UTC, Nov 19, 2026, AGP -

The cloud-based rare disease family registry market is projected to grow from $1.4 billion in 2025 to $1.65 billion in 2026, then reach $3.15 billion by 2030, according to The Business Research Company. The report points to precision medicine, patient advocacy, and cloud data tools as the main forces behind the surge.

Why it matters: - Cloud-based rare disease family registries are becoming a core tool for rare disease research, patient care, and clinical trial recruitment. - The market’s growth reflects stronger demand for centralized data systems that can combine genetic, clinical, and treatment information. - The shift matters for drug developers, researchers, and patient groups working on rare diseases and precision medicine.

What happened: - The Business Research Company released a report titled Cloud-Based Rare Disease Family Registry Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The market is projected to rise from $1.4 billion in 2025 to $1.65 billion in 2026. - That would equal a compound annual growth rate of 17.7%. - The market is forecast to grow at a 17.5% CAGR through 2030. - The report estimates the market will reach $3.15 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - A cloud-based rare disease family registry is an online platform that securely collects, stores, and manages health and family information related to rare diseases. - The system lets patients, families, and healthcare providers share data from any location. - The platform is designed to support research, improve patient care, and streamline clinical trial recruitment. - Historical growth has been driven by expanding rare disease research programs, stronger patient advocacy involvement, broader clinical trial networks, wider use of electronic data capture, and the need for centralized patient data systems. - Future growth is expected to come from more investment in orphan drug development, higher demand for real-world evidence, growth in precision medicine research, wider use of AI-powered data analytics, and more patient-centered research models. - The report flags wider adoption of cloud-based patient registries, more digital platforms for rare disease studies, integration of genomic and clinical datasets, better global trial recruitment tools, and stronger secure data-sharing practices as emerging trends. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, and updated graphics and tables. - The regional analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The report offers a free sample and full report through links provided in the release, including the free sample request and the full market report.

Between the lines: - Precision medicine is a key growth driver because it depends on detailed patient-level data tied to genetics, lifestyle, and treatment history. - The report cites a February 2024 finding from the Personalized Medicine Coalition that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - Seven of those therapies targeted cancer, and three addressed other conditions. - That jump suggests more commercial and research activity around personalized rare disease treatments. - Cloud-based registries benefit from that trend because they make it easier to organize the data needed for those therapies and related studies.

What's next: - Market growth is expected to stay strong as rare disease research expands and more stakeholders invest in digital infrastructure. - The next wave of adoption will likely focus on richer data integration, stronger privacy controls, and tools that improve patient recruitment across borders. - The report points to secure data sharing and AI-enabled analytics as areas to watch through 2030.

The bottom line: - Cloud-based rare disease family registries are moving from niche research tools to essential infrastructure for precision medicine and rare disease trials.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Global Tech News Palestine

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Global Tech News Palestine

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.